Aurobindo Pharma Ltd Share Price

Overview

Aurobindo Pharma Ltd share price is currently ₹1,582.71, up by ₹3.75 (0.24%) from its previous closing price of ₹1,578.96. The share price has gained 3.89% over the past month and gained 47.23% over the past year. The stock's 52-week low and high are ₹998.54 and ₹1,668.69, respectively. Aurobindo Pharma Ltd has a market capitalisation of ₹ 93,290.00 Cr. The share price was last updated on 25 Aug 2026, 09:39 AM IST.

Aurobindo Pharma Ltd

AUROPHARMA

₹0.00

₹3.75

0.24%

Healthcare

₹0.00(%)1D

Updated: 25 Aug 2026, 09:39:20 am IST

Market Data

Open Price

₹1,584.94

Prev. Close

₹1,578.96

₹1,579.05

Day Low

₹1,590.34

Day High

₹998.54

52 Week Low

₹1,668.69

52 Week High

HealthcarePharmaceuticals & Drugs

CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

24.70

Sector PE

42.03

PB Ratio

2.43

Sector PB

5.82

EPS

64.09

Dividend Yield

0.31

Today's Volume

32.154 K

5 Day Avg. Volume

656.869 K

PEG Ratio

45.74

Market Cap.

₹ 93,290.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Actions	Ex-Date	Record-Date
DividendsInterim Dividend of 400% at ₹4/Share	08-Aug-2025	08-Aug-2025

Mutual Fund Ownership

Mutual Fund Holder	Jun 26 Shares held	Jul 26 Shares held
HDFC Mid Cap Fund - Regular Plan - Growth	1.33 Cr	1.33 Cr no change
Quant ELSS Tax Saver Fund - Growth	66.52 Lac	66.52 Lac no change
SBI Large & Midcap Fund - Regular Plan - IDCW	53.57 Lac	53.57 Lac no change
Quant Mid Cap Fund - Growth	53.68 Lac	51.03 Lac (4.93%)
Quant Multi Cap Fund - Growth	42.57 Lac	42.57 Lac no change

Show all holdings

About Aurobindo Pharma Ltd 👋

Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology, non-oncology prescription formulation, and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is marketing its products globally in approximately 150 countries. Its subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltd, and others.